This HTML5 document contains 116 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n17https://global.dbpedia.org/id/
schemahttp://schema.org/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n16http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
n9http://commons.wikimedia.org/wiki/Special:FilePath/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
provhttp://www.w3.org/ns/prov#
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Priority_review
dbo:wikiPageWikiLink
dbr:Ultragenyx
Subject Item
dbr:Ultragenyx
rdf:type
dbo:Company wikidata:Q43229 wikidata:Q4830453 schema:Organization owl:Thing n16:Agent n16:SocialPerson dbo:Agent dbo:Organisation wikidata:Q24229398
rdfs:label
Ultragenyx
rdfs:comment
Ultragenyx is an American biopharmaceutical company involved in the Research and Development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
foaf:name
Ultragenyx Pharmaceutical Inc.
dbp:name
Ultragenyx Pharmaceutical Inc.
foaf:depiction
n9:Ultralgenyx_logo_new.svg
dcterms:subject
dbc:Pharmaceutical_companies_of_the_United_States dbc:Companies_listed_on_the_Nasdaq dbc:Companies_based_in_Marin_County,_California dbc:Biotechnology_companies_of_the_United_States
dbo:wikiPageID
66187793
dbo:wikiPageRevisionID
1113607429
dbo:wikiPageWikiLink
dbr:Vestronidase_alfa dbr:Biopharmaceutical dbr:Daiichi_Sankyo dbr:X-linked_hypophosphatemia dbr:Angelman_syndrome dbr:Russell_1000 dbr:Ornithine_transcarbamylase_deficiency dbr:Osteogenesis_imperfecta dbr:Oncogenic_osteomalacia dbr:Initial_public_offering dbr:Glycogen_storage_disease_type_III dbr:Burosumab dbr:Biotech dbr:Approved_drug dbr:GLUT1_deficiency dbc:Pharmaceutical_companies_of_the_United_States dbr:Adeno-associated_virus dbr:Emil_Kakkis dbr:Mucopolysaccharidosis dbr:Research_and_development dbr:Hereditary_inclusion_body_myopathy dbr:Biotechnology dbc:Companies_listed_on_the_Nasdaq dbr:Wilson's_disease dbr:Kyowa_Hakko_Kirin dbr:Metabolites dbc:Companies_based_in_Marin_County,_California dbr:Arcturus_Therapeutics dbr:Public_company dbc:Biotechnology_companies_of_the_United_States dbr:Haemophilia_A dbr:FDA dbr:Regeneron_Pharmaceuticals dbr:Antibody dbr:Citric_Acid_Cycle dbr:Drug_nomenclature dbr:Chief_executive_officer dbr:List_of_life_sciences dbr:Triheptanoin dbr:Evinacumab dbr:Novato,_California
owl:sameAs
n17:2oeb9 wikidata:Q30288872
dbp:wikiPageUsesTemplate
dbt:Increase dbt:Ubl dbt:Infobox_company dbt:Pharmaceutical_companies_of_the_United_States dbt:URL dbt:Start_date_and_age dbt:Reflist
dbo:thumbnail
n9:Ultralgenyx_logo_new.svg?width=300
dbp:hqLocationCity
dbr:Novato,_California
dbp:hqLocationCountry
U.S.
dbp:keyPeople
dbr:Emil_Kakkis
dbp:logo
Ultralgenyx_logo_new.svg
dbp:logoSize
230
dbp:numEmployees
893
dbp:revenue
2.71E8
dbp:type
dbr:Public_company
dbo:abstract
Ultragenyx is an American biopharmaceutical company involved in the Research and Development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami. Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. The company also has therapies approved outside the U.S. in Canada, Latin America, Europe, and Japan. In 2020 and 2021, Ultragenyx was named one of Deloitte’s fasting growing technology and life sciences companies in North America and one of the best companies to work for by BioSpace. Also in 2021, the company’s CEO, Emil Kakkis, was awarded the California Life Sciences Pantheon Leadership award.
dbp:areasServed
International
prov:wasDerivedFrom
wikipedia-en:Ultragenyx?oldid=1113607429&ns=0
dbo:wikiPageLength
17560
dbo:foundingYear
2010-01-01
dbo:numberOfEmployees
893
dbo:revenue
2.71E8
dbo:keyPerson
dbr:Emil_Kakkis
dbo:locationCity
dbr:Novato,_California
dbo:type
dbr:Public_company
foaf:isPrimaryTopicOf
wikipedia-en:Ultragenyx
Subject Item
dbr:Ultragenyx_Pharmaceutical
dbo:wikiPageWikiLink
dbr:Ultragenyx
dbo:wikiPageRedirects
dbr:Ultragenyx
Subject Item
dbr:Ultragenyx_Pharmaceutical_Inc.
dbo:wikiPageWikiLink
dbr:Ultragenyx
dbo:wikiPageRedirects
dbr:Ultragenyx
Subject Item
dbr:Vestronidase_alfa
dbo:wikiPageWikiLink
dbr:Ultragenyx
Subject Item
dbr:Emil_Kakkis
dbo:wikiPageWikiLink
dbr:Ultragenyx
dbo:institution
dbr:Ultragenyx
Subject Item
dbr:Monoclonal_antibody_therapy
dbo:wikiPageWikiLink
dbr:Ultragenyx
Subject Item
dbr:BIOTECanada
dbo:wikiPageWikiLink
dbr:Ultragenyx
Subject Item
dbr:Brisbane,_California
dbo:wikiPageWikiLink
dbr:Ultragenyx
Subject Item
dbr:HealthCap
dbo:wikiPageWikiLink
dbr:Ultragenyx
Subject Item
dbr:Dakin_Building
dbo:wikiPageWikiLink
dbr:Ultragenyx
Subject Item
dbr:Novato,_California
dbo:wikiPageWikiLink
dbr:Ultragenyx
Subject Item
dbr:Osteogenesis_imperfecta
dbo:wikiPageWikiLink
dbr:Ultragenyx
Subject Item
dbr:Arcturus_Therapeutics
dbo:wikiPageWikiLink
dbr:Ultragenyx
Subject Item
dbr:Biotechnology_industry_in_Boston
dbo:wikiPageWikiLink
dbr:Ultragenyx
Subject Item
dbr:Reagan-Udall_Foundation
dbo:wikiPageWikiLink
dbr:Ultragenyx
Subject Item
dbr:CDKL5_deficiency_disorder
dbo:wikiPageWikiLink
dbr:Ultragenyx
Subject Item
dbr:Guadalupe_Hayes-Mota
dbo:wikiPageWikiLink
dbr:Ultragenyx
Subject Item
dbr:Mucopolysaccharidosis
dbo:wikiPageWikiLink
dbr:Ultragenyx
Subject Item
dbr:Russell_1000_Index
dbo:wikiPageWikiLink
dbr:Ultragenyx
Subject Item
wikipedia-en:Ultragenyx
foaf:primaryTopic
dbr:Ultragenyx